dizocilpine-maleate and Carcinoma--Squamous-Cell

Despite recent improvements in treatment strategies, the results of chemotherapy in patients with advanced squamous cell carcinoma of the larynx are not satisfactory. Thus, the development of new approaches which influence specific metabolic pathways are needed. In the last decade, evidence has emerged implicating a role for glutamate as a signal mediator in tumors.. The presence of glutamate receptor subunits in two laryngeal cancer cell lines (RK33 and RK45) was evaluated by means of end-point PCR, real-time PCR, and immunocytochemistry.. Glutamate receptor subunits are differentially expressed in laryngeal cancer cell lines. In addition, we show that selected ionotropic glutamate receptor antagonists and metabotropic glutamate receptor 5 antagonist inhibit proliferation of laryngeal cancer cells. Glutamate antagonists also affected activity of extracellular signal-regulated kinases 1/2 in tumor cells.. Signaling through glutamate receptors may influence growth of laryngeal cancer cells and may constitute an adjunctive therapeutic target.

Topics: Benzodiazepines; Carcinoma, Squamous Cell; Cell Growth Processes; Cell Line, Tumor; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Humans; Laryngeal Neoplasms; Memantine; Microscopy, Confocal; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Receptors, Ionotropic Glutamate; Receptors, Metabotropic Glutamate; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger